Ongoing verification study supports compatibility of DeepChek® with the AVITI™ platform.
Expands opportunities in infectious disease sequencing workflows.
WOIPPY, FRANCE, June 9, 2026 /EINPresswire.com/ — ABL Diagnostics (FR001400AHX6 – “ABLD”), a pioneer in innovative molecular diagnostics and bioinformatics software, today announced progress in its analytical verification program evaluating the compatibility of its proprietary DeepChek® workflow (end-to-end library preparation and bioinformatics analysis) with the AVITI™ sequencing platform from Element Biosciences. The ongoing study represents an important step in ABL Diagnostics’ platform-agnostic strategy, which aims to provide laboratories with greater flexibility in selecting sequencing technologies while maintaining standardized analytical workflows.
Disruptive Technology Powering Genotyping Flexibility:
The AVITI™ platform from Element Biosciences is gaining attention in the NGS market through its proprietary Avidity Sequencing™ chemistry, offering configurable sequencing output through a dual independent flow-cell architecture. As stated by Molly He, CEO and Co-Founder of Element Biosciences, Element aims to ensure that “AVITI works in any research environment as a ‘plug-and-play’ system” (https://www.businesswire.com/news/home/20220608005220/en/Element-Biosciences-Announces-First-Customer-Shipments-and-New-Offerings-for-AVITI-System).
Through its ongoing verification efforts, ABL Diagnostics is assessing the performance of the DeepChek® workflow on the AVITI™ platform in comparison with established sequencing systems, including Illumina MiSeq® and iSeq™ 100. These evaluations are intended to support broader compatibility across multiple sequencing platforms and provide laboratories with increased operational flexibility.
Rigorous Methodology & Maximum Analytical Performance:
The internal study, executed under strict experimental controls, evaluates 48 clinical samples (two independent pools of 24) covering multiple molecular virology applications, including HIV, HBV, RSV, SARS-CoV-2, and Influenza, across whole genome sequencing, genotyping, subtyping, and resistance-associated mutation analysis.
A high level of analytical concordance between the AVITI™ platform and Illumina reference platforms is being assessed across key performance parameters, including:
– Genome coverage depth and uniformity.
– Variant detection and allele frequency estimation.
– Consensus sequence generation.
Dr. Sofiane Mohamed, Head of Research & Development at ABL Diagnostics, commented: “This verification study underscores the robust adaptability of the DeepChek® workflow. By harmonizing and standardizing sequencing data analysis irrespective of the underlying hardware platform, we are systematically dismantling the barriers to advanced NGS adoption in molecular microbiology.”
Market Context (Informational):
Next-generation sequencing (NGS) technologies continue to be adopted across research and clinical laboratory settings for pathogen characterization and molecular analysis. Market analyses indicate ongoing growth in sequencing applications, including infectious disease-related use cases. This information is provided for general informational purposes only.
Statements and Disclaimers:
This communication may contain forward-looking statements based on currently available information and assumptions. The verification study described herein remains ongoing and is subject to completion and final analysis. The results presented do not constitute a complete regulatory validation or demonstration of clinical performance. No claims are made regarding clinical benefit beyond the product’s cleared or approved intended use.
About ABL Diagnostics (ABLD)
ABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:
– Molecular polymerase chain reaction (PCR) detection – UltraGene, and
– Genotyping by DNA sequencing – DeepChek®.
ABL Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics’ customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.
ABL Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.
An expanding portfolio of microbiology products:
– HIV – Drug resistance testing, including a whole genome kit.
– SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.
– Microbiome and taxonomy – 16s/18s RNA-based analyses.
– Other viral and bacterial targets – Comprehensive molecular assays.
Integrated Solutions
– Real-time syndromic PCR tests
– Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.
– MediaChek® – Clinical Sample Collection Kits.
ABL Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.
Contact
ABL Diagnostics SA
Société anonyme au capital de 1 611 465,60 euros
Headquarters : 72C route de Thionville – 57140 WOIPPY
552 064 933 R.C.S. METZ Tel : +33 (0)7 83 64 68 50
Email : info@abldiagnostics.com
https://www.abldiagnostics.com/
Dr Sayada
ABL Diagnostics SA
+33 7 83 64 68 50
email us here
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
